Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piperacillin/tazobactam - NAEJA Pharmaceutical/Taiho Pharmaceutical

Drug Profile

Piperacillin/tazobactam - NAEJA Pharmaceutical/Taiho Pharmaceutical

Alternative Names: Tazobac; Tazobactam/piperacillin; Tazobactam/piperacillin 1:8 ratio product; Tazocel; Tazocilline; Tazocin; YP-18; Zosyn

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NAEJA Pharmaceutical; Taiho Pharmaceutical
  • Developer FUJIFILM Toyama Chemical; Taiho Pharmaceutical
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Penicillins; Piperazines
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Biliary tract infections; Cholangitis; Cholecystitis; Febrile neutropenia; Intra-abdominal infections; Nosocomial pneumonia; Peritonitis; Respiratory tract infections; Sepsis; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 01 Oct 2018 Taiho Pharmaceutical acquires marketing rights from Taisho Toyama Pharmaceutical for ZOSYN® in Japan
  • 19 May 2017 Launched for Skin and soft tissue infections in Japan (IV)
  • 18 May 2017 Registered for Skin and soft tissue infections in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top